ENDOMETRIAL CANCER RISK AFTER DISCONTINUING USE OF UNOPPOSED CONJUGATED ESTROGENS (CALIFORNIA, UNITED-STATES)

被引：18

作者：

FINKLE, WD

GREENLAND, S

MIETTINEN, OS

ZIEL, HK

机构：

[1] SO CALIF PERMANENTE MED GRP,DEPT OBSTET & GYNECOL,PASADENA,CA 91101

[2] UNIV CALIF LOS ANGELES,SCH PUBL HLTH,DEPT EPIDEMIOL,LOS ANGELES,CA 90024

[3] MCGILL UNIV,FAC MED,DEPT EPIDEMIOL & BIOSTAT,MONTREAL,PQ,CANADA

来源：

CANCER CAUSES & CONTROL | 1995年 / 6卷 / 02期

关键词：

CONJUGATED ESTROGENS; ENDOMETRIAL CANCER; ETIOLOGY; FEMALES; UNITED STATES;

D O I：

10.1007/BF00052769

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To examine the decline in risk of endometria cancer after discontinuation of use of conjugated estrogens, we conducted a case-control study in a prepaid health plan. We identified 318 patients who had endometrial cancer but had no history of bilateral oophorectomy and had been in the Southern California (United States) Raiser Foundation Health Wan for more than 10 years. For each patient, one or two control members were selected, 599 in all, matched for age and duration of membership at the time of cancer detection and who had had neither hysterectomy nor bilateral oophorectomy, A history of prescriptions for conjugated estrogens and of potential confounders was obtained for each subject by reviewing outpatient medical records. Rate ratios (RR) contrasting users with nonusers were estimated by time of latest prescription. We found that estrogen-induced risk of endometrial cancer decreases rapidly as the estrogen-free interval increases. The RR estimates, adjusted for duration of use and potential confounding factors, declined from 5.0 for those receiving their latest prescription within 24 months (95 percent confidence limits [CL] = 2.6-9.8), to 1.8 for those receiving their latest prescription within 24 to 48 months (CL = 0.9-3.7), to values near one for each latest prescription interval earlier than 48 months ago (P for trend = 0.00004), For those who used conjugated estrogens extensively (five or more prescriptions, five to 10 years ago), the RR estimate declined from 5.1 for those whose latest prescription was within two years to 0.6 yr for those whose latest prescription was four to five years previously (P for trend = 0.05).

引用

页码：99 / 102

页数：4

共 17 条

[1]

Voigt L.F., Weiss N.S., Epidemiology of endometrial cancer, Endometrial Cancer, pp. 1-21, (1989)

[2]

Herrinton L.J., Weiss N.S., Postmenopausal unopposed estrogens: characteristics of use in relation to the risk of endometrial carcinoma, Ann Epidemiol, 3, pp. 308-18, (1993)

[3]

Jick H., Watkins R.N., Hunter J.R., Et al., Replacement estrogens and endometrial cancer, N Engl J Med, 300, pp. 218-22, (1979)

[4]

Hulka B.S., Grion R.C., Greenberg B.G., Et al., “Alternative” controls in a case-control study of endometrial cancer and exogenous estrogen, Am J Epidemiol, 112, pp. 376-87, (1980)

[5]

Stavraky K.M., Collins J.A., Donner A., Wells G.A., A comparison of estrogen use by women with endometrial cancer, gynecologic disorders, and other illnesses, Am J Obstet Gynecol, 141, pp. 547-55, (1981)

[6]

Paganini-Hill A., Ross R.K., Henderson B.E., Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study, Br J Cancer, 59, pp. 445-7, (1989)

[7]

Rubin G.L., Peterson H.B., Lee N.C., Maes E.F., Wingo P.A., Becker S., Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies, Am J Obstet Gynecol, 162, pp. 148-54, (1990)

[8]

Weiss N.S., Szekely D.R., English D.R., Schweid A.I., Endometrial cancer in relation to patterns of menopausal estrogen use, JAMA, 242, pp. 261-4, (1979)

[9]

Buring J.E., Bain C.J., Ehrmann R.L., Conjugated estrogen use and risk of endometrial cancer, Am J Epidemiol, 124, pp. 434-41, (1986)

[10]

Mack T.M., Pike M.C., Henderson B.E., Et al., Estrogens and endometrial cancer in a retirement community, N Engl J Med, 294, pp. 1262-7, (1976)

← 1 2 →